Nath Bio-Genes (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.1 pts less than Nifty Microcap 250 and 8.2 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nath Bio-Genes reported standalone revenue of Rs. 4,569.36 lakhs for Q4 FY26 (vs Rs. 4,938.76 lakhs in Q4 FY25) and full-year revenue of Rs. 43,159.72 lakhs (FY25: Rs. 36,230.81 lakhs), representing approximately 19% revenue growth. Full-year net profit after tax stood at Rs. 4,442.57 lakhs (FY25: Rs. 4,214.01 lakhs), a growth of about 5.4%. The auditor issued an unmodified clean opinion with two emphasis of matter notes: recovery of Rs. 600.73 lakhs against previously provisioned farmer advances, and pending confirmations on certain trade receivables, payables, and loans. Operating cash flow turned negative at Rs. -1,391.44 lakhs in FY26 from positive Rs. 2,679.85 lakhs in FY25. Borrowings increased to Rs. 12,117.93 lakhs from Rs. 10,952.44 lakhs. The Board approved dividend of Rs. 2 per share (20%) and increased MD remuneration from Rs. 66 lakhs to Rs. 144 lakhs per annum. K.P. Sahasrabudhe & Co. was appointed as internal auditor for FY27.
The company shows steady revenue growth approaching 20% but PAT growth is modest at ~5%. The shift to negative operating cash flow and increased borrowings are concerning. The clean audit with emphasis of matter on outstanding confirmations and the large exceptional item from advance recovery suggests potential asset quality issues in the agriculture loan portfolio.